Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

EHA 2021

9 - 17 Jun 2021
Virtual, Netherlands
ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B...
Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
12 Jul 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethaso...
Prof Thierry Facon - Chu De Lille, Lille, France
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )
25 Jun 2021
The clinical value of maintenance in multiple myeloma
Prof Wee Joo Chng - National University of Singapore, Singapore
The clinical value of maintenance in multiple myeloma ( Prof Wee Joo Chng  - National University of Singapore, Singapore )
25 Jun 2021
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-r...
Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )
25 Jun 2021
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
25 Jun 2021
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refract...
Dr Claudio Cerchione - IRCCS, Meldola, Italy
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )
23 Jun 2021
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )
22 Jun 2021
CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL
Prof John Allan - Weill Cornell Medicine, New York, USA
CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL ( Prof John Allan - Weill Cornell Medicine, New York, USA )
17 Jun 2021
Interim results of a phase II study of blinatumomab plus ponatinib for Philadelp...
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia chromosome-positive ALL ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
17 Jun 2021
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leuka...
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
17 Jun 2021
EHA 2021: Latest in immunotherapy for R/R multiple myeloma
Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cav...
EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )
17 Jun 2021
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 ex...
Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
15 Jun 2021
GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL
Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlan...
GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL ( Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands )
15 Jun 2021
Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma
Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark
Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma ( Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark )
15 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )
14 Jun 2021
Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-...
Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA
Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )
11 Jun 2021
CLL14: Venetoclax plus obinutuzumab in untreated CLL
Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany
CLL14: Venetoclax plus obinutuzumab in untreated CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )
11 Jun 2021